BioSenic S.A. (ENXTBR: BIOS)
Health Care · Biotechnology · BE
€0.00
-9.09% today · -20.0% 1Y
BioSenic S.A. (ENXTBR: BIOS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.52M and employs 12 people.
Over the last twelve months the share price has lost 20.0%, trading between 0.00 and 0.00.
Tweenvest scores BioSenic S.A. across four factors: quality 9/100, value 52/100. Its strongest factor is value.
BIOS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.52M
- Revenue (TTM)
- $-2.80M
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- -1.60
- 52-week high
- €0.00
- 52-week low
- €0.00
- Avg volume (3M)
- —
- Shares outstanding
- 652.86M
- Employees
- 12
- Next earnings
- —
About BioSenic S.A.
BioSenic S.A., a biotechnology company located in Mont-Saint-Guibert, Belgium, is dedicated to progressing clinical therapeutic solutions. The firm utilizes two primary technology platforms: an innovative allogeneic cell and gene therapy system featuring distinct bone marrow-derived mesenchymal stromal cells designed for convenient on-site hospital storage; and an Arsenic Trioxide platform. The latter is deployed in immuno-oncology to target illnesses such as graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's leading experimental drug, ALLOB, is currently undergoing a Phase IIb clinical trial for patients with complicated tibial fractures.
- ISIN
- BE0974280126
- Listed since
- Feb 3, 2015
- Exchange
- Euronext Brussels
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €875.40 | +1.30% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.